- Home
- NAZ vs CGEN Comparison
NAZ vs CGEN Comparison
Compare NAZ & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAZ
- CGEN
- Stock Information
- Founded
- NAZ 1992
- CGEN 1993
- Country
- NAZ United States
- CGEN Israel
- Employees
- NAZ N/A
- CGEN N/A
- Industry
- NAZ Finance/Investors Services
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NAZ Finance
- CGEN Health Care
- Exchange
- NAZ Nasdaq
- CGEN Nasdaq
- Market Cap
- NAZ 139.4M
- CGEN 142.4M
- IPO Year
- NAZ N/A
- CGEN 2000
- Fundamental
- Price
- NAZ $11.96
- CGEN $2.25
- Analyst Decision
- NAZ
- CGEN Strong Buy
- Analyst Count
- NAZ 0
- CGEN 1
- Target Price
- NAZ N/A
- CGEN $4.00
- AVG Volume (30 Days)
- NAZ 18.3K
- CGEN 898.9K
- Earning Date
- NAZ 01-01-0001
- CGEN 03-04-2025
- Dividend Yield
- NAZ 3.69%
- CGEN N/A
- EPS Growth
- NAZ N/A
- CGEN N/A
- EPS
- NAZ N/A
- CGEN 0.02
- Revenue
- NAZ N/A
- CGEN $59,852,000.00
- Revenue This Year
- NAZ N/A
- CGEN $57.27
- Revenue Next Year
- NAZ N/A
- CGEN N/A
- P/E Ratio
- NAZ N/A
- CGEN $125.59
- Revenue Growth
- NAZ N/A
- CGEN 698.03
- 52 Week Low
- NAZ $9.22
- CGEN $1.35
- 52 Week High
- NAZ $11.37
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- NAZ 57.36
- CGEN 81.70
- Support Level
- NAZ $11.90
- CGEN $1.92
- Resistance Level
- NAZ $12.16
- CGEN $2.16
- Average True Range (ATR)
- NAZ 0.16
- CGEN 0.15
- MACD
- NAZ 0.08
- CGEN 0.07
- Stochastic Oscillator
- NAZ 77.27
- CGEN 88.90
About NAZ Nuveen Arizona Quality Municipal Income Fund
Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. Its primary investment objective is to provide current income exempt from both regular federal income taxes and Arizona individual income taxes. The fund's secondary objective is to enhance the portfolio value relative to the Arizona municipal bond market through investments in tax-exempt Arizona Municipal Obligations that, in the opinion of the Fund's investment adviser, are underrated or undervalued or represent municipal market sectors that are undervalued.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.